Market: NASD |
Currency: USD
Address: 321 Summer Street
Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
📈 Inozyme Pharma, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$10.00
-
Upside/Downside from Analyst Target:
150.00%
-
Broker Call:
2
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Inozyme Pharma, Inc.
| Date | Reported EPS |
|---|
| 2025-08-05 | - |
| 2025-05-14 | -0.44 |
| 2025-03-10 | -0.42 |
| 2024-11-05 | -0.39 |
| 2024-08-06 | -0.44 |
| 2024-05-07 | -0.38 |
| 2024-03-12 | -0.35 |
| 2023-11-07 | -0.29 |
| 2023-08-08 | -0.35 |
| 2023-05-09 | -0.4 |
| 2023-03-22 | -0.31 |
| 2022-11-10 | -0.38 |
| 2022-08-15 | -0.38 |
| 2022-05-10 | -0.71 |
| 2022-03-15 | -0.79 |
| 2021-11-09 | -0.6 |
| 2021-08-11 | -0.53 |
| 2021-05-12 | -0.47 |
| 2021-03-25 | -0.3 |
| 2020-11-12 | -0.57 |
| 2020-09-03 | -7.57 |
📰 Related News & Research
No related articles found for "inozyme pharma".
